Literature DB >> 23372365

Magnifying chromoendoscopy combined with immunohistochemical staining for early diagnosis of gastric cancer.

Xian-Mei Meng1, Yi Zhou, Tong Dang, Xu-Yang Tian, Jie Kong.   

Abstract

AIM: To assess the diagnostic value of using magnifying chromoendoscopy combined with immunohistochemical staining of proliferating cell nuclear antigen (PCNA) and p53 in the detection of gastric precancerous lesions.
METHODS: Ninety-five patients who were treated for abdominal discomfort, abdominal pain, bloating, and acid reflux at our hospital from January 2010 to December 2011 were included in the study. An ordinary gastroscopic procedure was initially performed to select the lesions. All subjects underwent magnifying chromoendoscopy to observe morphological changes of gastric pits. Biopsies were then taken from each area of interest and sent for pathological examination and detection of PCNA and p53 expression by immunohistochemistry. An immunoreactivity score for each lesion was calculated. Based on immunoreactivity scores, immunohistochemical staining was then considered.
RESULTS: Compared to intestinal metaplasia, gastric pits were more diverse in size, more irregular in shape, and more disorderly in arrangement in moderate and severe dysplasia. PCNA and p53 expression was significantly higher in precancerous lesions (intestinal metaplasia and dysplasia) than in chronic gastritis. PCNA expression showed an upward trend in types A-F pits. The number of cases that showed strong PCNA positivity increased significantly with an increase in the severity of lesions. Rank sum test for independent samples showed that p53 expression was significantly higher in types E and F pits than in types A-D pits (H = 33.068, P = 0.000). Rank sum test for independent samples showed that PCNA expression was significantly higher in types E and F pits than in types A-D pits (H = 31.791, P = 0.001).
CONCLUSION: The presence of types E and F pits, in which p53 and PCNA are highly expressed, is highly suggestive of the occurrence of early cancer, and patients developing these changes should be closely followed.

Entities:  

Keywords:  Early gastric cancer; Gastric precancerous lesions; Magnifying chromoendoscopy; Proliferating cell nuclear antigen; p53

Mesh:

Substances:

Year:  2013        PMID: 23372365      PMCID: PMC3554827          DOI: 10.3748/wjg.v19.i3.404

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Classification of Barrett's epithelium by magnifying endoscopy.

Authors:  Takao Endo; Teruhito Awakawa; Hiroaki Takahashi; Yoshiaki Arimura; Fumio Itoh; Kentaro Yamashita; Sigeru Sasaki; Hiroyuki Yamamoto; Xiufen Tang; Kohzoh Imai
Journal:  Gastrointest Endosc       Date:  2002-05       Impact factor: 9.427

2.  Autoantibody to a nuclear antigen in proliferating cells.

Authors:  K Miyachi; M J Fritzler; E M Tan
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

3.  Cancer statistics, 1997.

Authors:  S L Parker; T Tong; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1997 Jan-Feb       Impact factor: 508.702

4.  [Inhibition effect of p53 antisense RNA on malignant phenotype of colorectal cancer cells].

Authors:  J Cao; L Teng; X Cai
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1997-03

5.  Detection and classification of early squamous cell esophageal cancer.

Authors:  M Endo; T Kawano
Journal:  Dis Esophagus       Date:  1997-07       Impact factor: 3.429

6.  [Changes of gastric pits in intestinal metaplasia of gastric mucosa].

Authors:  A Wang; S Ye; S Lin
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1997-05

7.  Increased proliferative activity caused by loss of p21(WAF1/CIP1) expression and its clinical significance in patients with early-stage gastric carcinoma.

Authors:  Hiroshi Noda; Yoshihiko Maehara; Koji Irie; Yoshihiro Kakeji; Tomohiro Yonemura; Keizo Sugimachi
Journal:  Cancer       Date:  2002-04-01       Impact factor: 6.860

8.  Routine endoscopy using a magnifying endoscope for gastric cancer diagnosis.

Authors:  H Tajiri; T Doi; H Endo; T Nishina; T Terao; I Hyodo; K Matsuda; K Yagi
Journal:  Endoscopy       Date:  2002-10       Impact factor: 10.093

9.  Usefulness of magnifying endoscopy in the diagnosis of early gastric cancer.

Authors:  Y Otsuka; Y Niwa; N Ohmiya; N Ando; A Ohashi; Y Hirooka; H Goto
Journal:  Endoscopy       Date:  2004-02       Impact factor: 10.093

10.  Endoscopic patterns of gastric mucosa and its clinicopathological significance.

Authors:  Jian-Min Yang; Lei Chen; Yu-Lin Fan; Xiang-Hong Li; Xin Yu; Dian-Chun Fang
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

View more
  4 in total

1.  Expression of p-STAT3 and vascular endothelial growth factor in MNNG-induced precancerous lesions and gastric tumors in rats.

Authors:  Xiao-Yan Wang; Lou-Lei Wang; Xuan Zheng; Li-Na Meng; Bin Lyu; Hai-Feng Jin
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

2.  Spectrum- and time-resolved endogenous multiphoton signals reveal quantitative differentiation of premalignant and malignant gastric mucosa.

Authors:  Xi Li; Hui Li; Xingzhen He; Tingai Chen; Xianyuan Xia; Chunxia Yang; Wei Zheng
Journal:  Biomed Opt Express       Date:  2018-01-08       Impact factor: 3.732

3.  Interaction of Cyclooxygenase-2 with Helicobacter pylori Induces Gastric Chronic Nonresolving Inflammation and the Formation of Syndrome of Internal Block of Static Blood in Helicobacter pylori-Related Gastric Diseases.

Authors:  Yun-Kai Dai; Yun-Zhan Zhang; Dan-Yan Li; Xu Chen; Lin Gong; Qi Luo; Shao-Yang Lan; Bin Chen; Jian-Yu Wu; Zi-Jing Zhang; Meng-Xin Huang; Jin-Tong Ye; Wei-Jing Chen; Ru-Liu Li; Ling Hu
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-06       Impact factor: 2.629

4.  Identification of ALDH3A2 as a novel prognostic biomarker in gastric adenocarcinoma using integrated bioinformatics analysis.

Authors:  Zhenhua Yin; Dejun Wu; Jianping Shi; Xiyi Wei; Nuyun Jin; Xiaolan Lu; Xiaohan Ren
Journal:  BMC Cancer       Date:  2020-11-04       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.